ArticleRespiratory medicine2025
Bronchodilator Response: Utility and implications in patients undergoing hematopoietic stem cell transplantation.
Article in Respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBronchodilator response (BDR) assessment is routinely included in pulmonary evaluation before hematopoietic cell transplantation (HCT), but its prognostic significance remains uncertain. Recent European Respiratory Society/American Thoracic Society (ERS/ATS) criteria changes complicate interpretation. RESEARCH QUESTION: To examine associations between BDR and clinical outcomes in HCT recipients and compare prognostic utility of traditional versus revised BDR criteria. STUDY DESIGN AND
methodsIn this single-center study of 1,255 adult allogeneic HCT recipients (2005-2021), we assessed BDR using both 2005 criteria (≥12 % and ≥200 mL increase in FEV
resultsAmong patients (58 % male, mean age 51.3 ± 13.6 years), positive BDR frequency was low (11.5 % by 2005 criteria, 14.2 % by 2022 criteria), with high concordance (>94 %). BDR did not predict BOS development, with similar pre-transplant FEV
interpretationBDR testing provides minimal additional prognostic information beyond baseline lung function assessment in HCT recipients and does not predict BOS development. Our findings support that BOS represents a fibroproliferative process distinct from disorders characterized by airway hyperresponsiveness, suggesting bronchodilator testing could be eliminated from standard HCT protocols without compromising risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.